Last quarter (Q4 2023), IDEAYA Biosciences's total revenue was $3.92M, a decrease of -86.79% from the same quarter last year. In Q4, IDEAYA Biosciences's net income was $-33.95M. See IDEAYA Biosciences’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 19.37M	$ 23.39M	$ 50.93M	$ 27.94M	$ 19.54M	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 19.37M	$ 23.39M	$ 50.93M	$ 27.94M	-	-
Operating Expense	$ 85.78M	$ 157.81M	$ -113.43M	$ 78.21M	$ 54.88M	$ 44.27M
Operating Income	$ -127.35M	$ -134.43M	$ -62.50M	$ -50.27M	$ -35.34M	$ -44.27M
Net Non Operating Interest Income Expense	$ 4.88M	-	$ 3.85M	$ 506.00K	$ 849.00K	$ 2.30M
Other Income Expense	$ -12.74M	$ -21.47M	-	-	-	$ 8.00K
Pretax Income	$ -109.72M	$ -112.96M	$ -58.66M	$ -49.76M	$ -34.49M	$ -41.98M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -109.72M	$ -112.96M	$ -58.66M	$ -49.76M	$ -34.49M	$ -41.98M
Basic EPS	$ -2.40	$ -1.96	$ -1.42	$ -1.41	$ -1.40	$ -3.36
Diluted EPS	$ -2.04	$ -1.96	$ -1.42	$ -1.41	$ -1.40	$ -3.36
Basic Average Shares	$ 211.52M	$ 57.52M	$ 41.44M	$ 35.25M	$ 24.72M	$ 12.50M
Diluted Average Shares	$ 211.52M	$ 57.52M	$ 41.44M	$ 35.25M	$ 24.72M	$ 12.50M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 85.78M	$ 157.81M	$ -113.43M	$ 78.21M	$ 54.88M	$ 44.27M
Net Income From Continuing And Discontinued Operation	$ -109.72M	$ -112.96M	$ -58.66M	$ -49.76M	$ -34.49M	$ -41.98M
Normalized Income	$ -48.89M	$ -89.24M	-	-	$ -34.49M	$ -41.98M
Interest Expense	-	-	-	-	-	-
EBIT	$ -111.96M	$ -112.96M	$ -58.66M	$ -49.76M	$ -35.34M	$ -44.27M
EBITDA	$ -118.07M	$ -120.51M	$ -57.25M	$ -46.20M	$ -33.96M	$ -43.03M

Currency in USD

IDEAYA Biosciences Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing